PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple myeloma |
| Phenotype | C0005940|bone disease |
| Sentences | 27 |
| PubMedID- 22952578 | Furthermore, studies aimed at clarifying the importance of osteoporosis in the bone disease associated with multiple myeloma, as well as the mechanism(s) involved, will help provide the rationale for targeting this component of the disease. |
| PubMedID- 25628928 | Osteolytic bone disease in multiple myeloma (mm) is associated with upregulated osteoclast activity. |
| PubMedID- 26579531 | bone disease, the hallmark of multiple myeloma (mm), is characterized by the presence of pure lytic lesions instead of solid tumors [1, 2]. |
| PubMedID- 20722619 | For over 2 decades bisphosphonates have been successfully used to treat the tumour-induced bone disease associated with multiple myeloma. |
| PubMedID- 22498739 | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the medical research council myeloma ix trial. |
| PubMedID- 25187738 | bone disease in multiple myeloma: pathophysiology and management. |
| PubMedID- 21991938 | Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. |
| PubMedID- 22726547 | bone disease in patients with multiple myeloma (mm) is characterized by increase in the numbers and activity of bone-resorpting osteoclasts and decrease in the number and function of bone-formation osteoblasts. |
| PubMedID- 25626302 | Osteolytic bone disease in multiple myeloma (mm) affects more than 80% of patients. |
| PubMedID- 24249482 | The effects of bortezomib on bone disease in patients with multiple myeloma. |
| PubMedID- 23431957 | Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. |
| PubMedID- 22454220 | Zoledronic acid (zol), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal-related events (sres) in multiple myeloma (mm) patients with bone disease. |
| PubMedID- 21649546 | Traditionally, the skeletal survey has been the standard modality for the detection of osteolytic bone disease in multiple myeloma. |
| PubMedID- 24074513 | Objectives: bone disease is one of the hallmarks of multiple myeloma (mm). |
| PubMedID- 22902442 | bone disease associated with multiple myeloma(mm)is characterized by increased osteoclast activity and suppressed osteoclast function because of some factors produced by myeloma cells, leading to severe osteolytic lesions. |
| PubMedID- 21732484 | multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses. |
| PubMedID- 24164102 | Zoledronic acid (zol) is frequently used for the treatment of bone disease in patients with multiple myeloma and breast cancer with metastasis to bone. |
| PubMedID- 20572008 | Our group has examined their role in the progression of the osteolytic bone disease associated with multiple myeloma. |
| PubMedID- 24656650 | Bone marrow plasma macrophage inflammatory protein protein-1 alpha(mip-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. |
| PubMedID- 20863761 | Interpretation: monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma. |
| PubMedID- 23417027 | Given the prevalence of osteolytic bone disease in multiple myeloma (mm), novel therapies targeting bone microenvironment are essential. |
| PubMedID- 24433088 | Management of bone disease in multiple myeloma. |
| PubMedID- 23416846 | No anabolic drugs are currently approved to treat multiple myeloma (mm)-induced bone disease and the anti-mm agent bortezomib exhibits the anabolic effects in the clinic. |
| PubMedID- 21745013 | bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. |
| PubMedID- 20664052 | Osteoclast (oc)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. |
| PubMedID- 21569702 | Objective: to explore the difference of effects of two regimens (bortezomib and dexamethasone, bd; and thalidomide and dexamethasone, td) on bone disease in multiple myeloma (mm). |
| PubMedID- 24381787 | Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. |
Page: 1